市場調查報告書

感染疾病治療藥的全球市場:成長,趨勢,及預測

Infectious Disease Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921240
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
感染疾病治療藥的全球市場:成長,趨勢,及預測 Infectious Disease Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

傳染病藥物全球市場的主要成長要素包括政府和非營利組織的意識提升活動,傳染病的傳播以及增加的研發資金。此外,在預測期內,傳染病流行率的上升預計將增加對藥品的需求並推動整體市場增長。

本報告提供全球感染疾病治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各疾病·治療藥·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 政府及非營利組織的活動
    • 感染疾病的盛行率增加
    • 研究開發的資金籌措
  • 阻礙市場要素
    • 新興國家的診斷和治療的低滲透率
    • 藥的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各疾病
    • HIV
    • 流感
    • 肝炎
    • 結核
    • 瘧疾
    • 其他
  • 各治療藥物
    • 抗菌劑
    • 抗病毒藥物
    • 驅蟲劑
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AbbVie Inc
    • Boehringer Ingelheim GmbH
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Janssen Pharmaceutical
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc
    • Sanofi SA
    • 武田藥品工業株式會社

第7章 市場機會及今後趨勢

目錄
Product Code: 67059

Market Overview

The major factors for the growth of the infectious disease drugs market include the rising awareness activities by various government and non-profit organizations, increasing prevalence of infectious diseases, and rising funding for the research and development.

The rising prevalence of infectious diseases is expected to boost the overall growth of the market over the forecast period. According to the World Health Organization (WHO), it is estimated that in 2018, nearly 37.9 million individuals had HIV, globally. It has been identified that most of this prevalence is in low and middle-income countries, with an estimated 66% living in Sub-Saharan Africa. According to the Joint United Nations Program on HIV/AIDS (UNAIDS) in 2016, around 1.8 million people with new HIV infection were reported, worldwide. Similarly, as per the WHO's 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. Thus, rising cases of infectious diseases are expected to increase the demand for drugs resulting in high growth of the market.

Scope of the Report

As per the scope of this report, infectious disease is disorders caused by organisms such as bacteria, viruses, fungi or parasites and there are various categories of the drugs used in the treatment of the infectious diseases. The market is segmented by disease, treatment, and geography.

Key Market Trends

HIV Segment is expected to hold Significant Market Share over the Forecast Period

HIV continues to be a major public health issue worldwide. South Africa accounts for a third of all new HIV infections in Southern Africa. The market size has been found to be significantly increased largely due to the expansion of antiretroviral therapy (ART). According to the UNAIDS data, in 2017 an estimated 36.9 million people were living with HIV globally. Around 25% of these do not know that they have HIV virus infection. Therefore in 2017, 940,000 people died due to these AIDS-related illnesses. Furthermore, according to the CDC data in 2017, 38,739 people thus received HIV diagnosis in the U.S. According to Avert, the United Kingdom (UK) has been found with a relatively small, concentrated HIV epidemic, with an estimated 101,600 people living with HIV in the year 2017. Therefore in the same year, 4,363 people were being newly diagnosed with HIV. Thus, owing to the rising prevalence of HIV the market is expected to witness high growth

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest infectious disease drug market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure. As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population. Furthermore, the antibiotic prescription rate is relatively high in the United States. In addition, the trend varies significantly, based on the provider in a particular state. Also, there is a rising prevalence of HIV in the United States and there is a rise in approval for the new disease treatment which is expected to boost the growth of the market. For instance, recently, in 2018, Gilead Sciences Inc. received approval from the US Food and Drug Administration (FDA), for Biktarvy, a daily single-tablet regimen (STR), for the treatment of HIV-1 infection. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Boehringer Ingelheim GmbH, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Company Limited

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising awareness activities by various Government and Non-profit Organizations
    • 4.2.2 Increasing Prevalence of Infectious Diseases
    • 4.2.3 Rising Funding for the Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries
    • 4.3.2 Side Effects of the Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease
    • 5.1.1 HIV
    • 5.1.2 Influenza
    • 5.1.3 Hepatitis
    • 5.1.4 Tuberculosis
    • 5.1.5 Malaria
    • 5.1.6 Other
  • 5.2 By Treatment
    • 5.2.1 Antibacterial
    • 5.2.2 Antiviral
    • 5.2.3 Antiparasitic
    • 5.2.4 Other
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc
    • 6.1.2 Boehringer Ingelheim GmbH
    • 6.1.3 Gilead Sciences, Inc.
    • 6.1.4 GlaxoSmithKline plc
    • 6.1.5 Janssen Pharmaceutical
    • 6.1.6 Merck & Co., Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc
    • 6.1.9 Sanofi SA
    • 6.1.10 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS